The Medicines and Healthcare products Regulatory Agency of the United Kingdom announced it has approved the medicine tarlatamab, Imdyllytra, to treat adult patients with small cell lung cancer that has spread throughout the lungs and/or to other parts of the body. “This approval has been granted under Project Orbis, an innovative programme that allows participating regulators to review and approve applications for promising cancer treatments quickly and efficiently. SCLC is one of the two main forms of primary lung cancer, accounting for around 1 in 7 of all lung cancers. It is less common than non-small-cell lung cancer and spreads more quickly,” the MHRA stated. The new marketing authorization was granted on December 31 to Amgen (AMGN) Limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Is Amgen (NASDAQ:AMGN) a High-Quality Dividend Stock on Sale?
- Novo obesity data positive for Eli Lilly and Amgen, says UBS
- Caterpillar, Epam among additions to Jefferies Franchise Picks list
- Viridian Therapeutics price target raised to $47 from $44 at RBC Capital
- A Dissapointing Week for Dow Jones Industrial Average Puts It in the Red